Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Plos Pathogens
|
September 24, 2010
The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription
Benjamin Morin, Bruno Coutard, Michaela Lelke, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 30, 2011
Adaptive human behavior in epidemiological models
Eli P Fenichel, Carlos Castillo-Chavez, M G Ceddia, et al.
Ecohealth
|
September 20, 2014
Merging economics and epidemiology to improve the prediction and management of infectious disease
Charles Perrings, Carlos Castillo-Chavez, Gerardo Chowell, et al.
Cancer Cell
|
June 13, 2018
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
Jeremy D Waight, Dhan Chand, Sylvia Dietrich, et al.
Nature Communications
|
June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicity
Yury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2026
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial
Haitham Mirghani, Anne Aupérin, Caroline Even, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2026
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma
Victor Malassigné, Julien Puech, Sandrine Imbeaud, et al.
Plos One
|
April 5, 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
Randi B Gombos, Ana Gonzalez, Mariana Manrique, et al.
Cancer Discovery
|
July 31, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Dhan Chand, David A Savitsky, Shanmugarajan Krishnan, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Plos Pathogens
|
September 24, 2010
The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription
Benjamin Morin, Bruno Coutard, Michaela Lelke, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 30, 2011
Adaptive human behavior in epidemiological models
Eli P Fenichel, Carlos Castillo-Chavez, M G Ceddia, et al.
Ecohealth
|
September 20, 2014
Merging economics and epidemiology to improve the prediction and management of infectious disease
Charles Perrings, Carlos Castillo-Chavez, Gerardo Chowell, et al.
Cancer Cell
|
June 13, 2018
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
Jeremy D Waight, Dhan Chand, Sylvia Dietrich, et al.
Nature Communications
|
June 23, 2023
Molecular mechanism of phosphopeptide neoantigen immunogenicity
Yury Patskovsky, Aswin Natarajan, Larysa Patskovska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2026
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial
Haitham Mirghani, Anne Aupérin, Caroline Even, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2026
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma
Victor Malassigné, Julien Puech, Sandrine Imbeaud, et al.
Plos One
|
April 5, 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
Randi B Gombos, Ana Gonzalez, Mariana Manrique, et al.
Cancer Discovery
|
July 31, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Dhan Chand, David A Savitsky, Shanmugarajan Krishnan, et al.
Page
of 3